Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Aptar Pharma advances digital offerings

Partners up with digital therapeutics company Propeller Health

AptarFurther strengthening pharma’s stance in the digital health field, prescription drug and consumer healthcare group Aptar Pharma has teamed up with Propeller Health in a bid to develop digital medicines in multiple therapeutic areas.

The “comprehensive” platform, which will span inhaled, injectable, nasal and dermal medicine delivery forms, will combine software with connected drug delivery devices.

Aptar Pharma will work with its new partner together with pharmaceutical and healthcare associates to accelerate the development, manufacturing and commercialisation of digital medicines for marketed and pipeline brands.

Propeller and Aptar Pharma will co-market the platform, with the former managing digital services and the latter handling device development, manufacturing and supply chain.

David Van Sickle, co-founder and CEO of Propeller, said: “Propeller draws on nearly a decade of experience pioneering digital respiratory medicines and putting them to work in healthcare organizations around the world.

“Our end-to-end infrastructure enables fast, flexible and secure development and commercialisation of digital medicines.”

Digital therapeutics, dubbed ‘digiceuticals’, has been somewhat of a focus for the industry as of late, with studies showing that this particular therapeutic advancement can help personalise treatments, monitor patients in real-time, detect day-to-day changes in disease conditions and increase patient adherence.

Salim Haffar, president of Aptar Pharma, commented: we are excited to broaden our offerings as we continue this journey towards improved patient care and clinical outcomes by growing our partnership with Propeller Health the leader in their field of digital therapeutics

The two companies initially partnered in 2016 to develop, what the companies say, is the world’s first fully-integrated connected metered dose inhaler (cMDI).

In addition to the expanded partnership, Aptar Pharma has made a strategic equity investment of $10m in Propeller Health during their latest funding round.

Article by
Gemma Jones

7th June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics